Cargando…
Bioactive Nanoparticles for Cancer Immunotherapy
Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321368/ https://www.ncbi.nlm.nih.gov/pubmed/30518139 http://dx.doi.org/10.3390/ijms19123877 |
_version_ | 1783385425786699776 |
---|---|
author | Poilil Surendran, Suchithra Moon, Myeong Ju Park, Rayoung Jeong, Yong Yeon |
author_facet | Poilil Surendran, Suchithra Moon, Myeong Ju Park, Rayoung Jeong, Yong Yeon |
author_sort | Poilil Surendran, Suchithra |
collection | PubMed |
description | Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system is a suitable strategy to be applied for cancer treatment. Usage of nanoparticle systems for delivery of immunotherapeutic agents to the body being widely studied and found to be a promising area of research to be considered and investigated further. Nanoparticles for immunotherapy would be one of the effective treatment options for cancer therapy in the future due to their high specificity, efficacy, ability to diagnose, imaging, and therapeutic effect. Among the many nanoparticle systems, polylactic-co-glycolic acid (PLGA) nanoparticles, liposomes, micelles, gold nanoparticles, iron oxide, dendrimers, and artificial exosomes are widely used for immunotherapy of cancer. Moreover, the combination therapy found to be the more effective way of treating the tumor. Here, we review the current trends in nanoparticle therapy and efficiency of these nanosystems in delivering antigens, adjuvants, therapeutic drugs, and other immunotherapeutic agents. This review summarizes the currently available bioactive nanoparticle systems for cancer immunotherapy. |
format | Online Article Text |
id | pubmed-6321368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63213682019-01-07 Bioactive Nanoparticles for Cancer Immunotherapy Poilil Surendran, Suchithra Moon, Myeong Ju Park, Rayoung Jeong, Yong Yeon Int J Mol Sci Review Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system is a suitable strategy to be applied for cancer treatment. Usage of nanoparticle systems for delivery of immunotherapeutic agents to the body being widely studied and found to be a promising area of research to be considered and investigated further. Nanoparticles for immunotherapy would be one of the effective treatment options for cancer therapy in the future due to their high specificity, efficacy, ability to diagnose, imaging, and therapeutic effect. Among the many nanoparticle systems, polylactic-co-glycolic acid (PLGA) nanoparticles, liposomes, micelles, gold nanoparticles, iron oxide, dendrimers, and artificial exosomes are widely used for immunotherapy of cancer. Moreover, the combination therapy found to be the more effective way of treating the tumor. Here, we review the current trends in nanoparticle therapy and efficiency of these nanosystems in delivering antigens, adjuvants, therapeutic drugs, and other immunotherapeutic agents. This review summarizes the currently available bioactive nanoparticle systems for cancer immunotherapy. MDPI 2018-12-04 /pmc/articles/PMC6321368/ /pubmed/30518139 http://dx.doi.org/10.3390/ijms19123877 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Poilil Surendran, Suchithra Moon, Myeong Ju Park, Rayoung Jeong, Yong Yeon Bioactive Nanoparticles for Cancer Immunotherapy |
title | Bioactive Nanoparticles for Cancer Immunotherapy |
title_full | Bioactive Nanoparticles for Cancer Immunotherapy |
title_fullStr | Bioactive Nanoparticles for Cancer Immunotherapy |
title_full_unstemmed | Bioactive Nanoparticles for Cancer Immunotherapy |
title_short | Bioactive Nanoparticles for Cancer Immunotherapy |
title_sort | bioactive nanoparticles for cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321368/ https://www.ncbi.nlm.nih.gov/pubmed/30518139 http://dx.doi.org/10.3390/ijms19123877 |
work_keys_str_mv | AT poililsurendransuchithra bioactivenanoparticlesforcancerimmunotherapy AT moonmyeongju bioactivenanoparticlesforcancerimmunotherapy AT parkrayoung bioactivenanoparticlesforcancerimmunotherapy AT jeongyongyeon bioactivenanoparticlesforcancerimmunotherapy |